Publication: An Examining Progress in Research: Cost-effectiveness of Cardiovascular Disease Prevention Using the Markov Model
Issued Date
2024
Resource Type
Resource Version
Accepted Manuscript
Language
eng
File Type
application/pdf
ISSN
2350-983x
Journal Title
Integrated Social Science Journal
Volume
11
Issue
2
Start Page
187
End Page
201
Access Rights
open access
Rights
ผลงานนี้เป็นลิขสิทธิ์ของมหาวิทยาลัยมหิดล ขอสงวนไว้สำหรับเพื่อการศึกษาเท่านั้น ต้องอ้างอิงแหล่งที่มา ห้ามดัดแปลงเนื้อหา และห้ามนำไปใช้เพื่อการค้า
Rights Holder(s)
Department of Social Sciences Faculty of Social Sciences and Humanities Mahidol University
Bibliographic Citation
Integrated Social Science Journal. Vol. 11, No. 2 (July-December 2024), 187-201
Suggested Citation
Mayuree Yotawut An Examining Progress in Research: Cost-effectiveness of Cardiovascular Disease Prevention Using the Markov Model. Integrated Social Science Journal. Vol. 11, No. 2 (July-December 2024), 187-201. 201. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/109582
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
An Examining Progress in Research: Cost-effectiveness of Cardiovascular Disease Prevention Using the Markov Model
Author(s)
Abstract
This article reviews three-volume collection of previously published articles on cost-effectiveness in cardiovascular disease prevention. Firstly, cost–effectiveness analysis of genetic screening for the Taq1B polymorphism in the secondary prevention of coronary heart disease is conducted. Secondly, a “polypill” aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America, and lastly, the cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany is assessed, based on the Treating to New Targets study. All three articles in this paper demonstrate how the Markov model can control strategy in terms of cost savings and increase the mean of quality-adjusted life-years (QALYs). Moreover, the Markov model can be used to demonstrate how healthcare systems can control the cost-effectiveness of drug use in terms of cardiovascular disease related to health benefits, costs, and quality-adjusted life-years (QALYs). In conclusion, employing the Markov model through other interventions, especially in the case of health benefits, cost savings, and quality-adjusted life-years (QALYs) is the main recommendation of this article.